WO2007108744A3 - Novel quinazolines as 5-ht6 modulators - Google Patents

Novel quinazolines as 5-ht6 modulators Download PDF

Info

Publication number
WO2007108744A3
WO2007108744A3 PCT/SE2007/000254 SE2007000254W WO2007108744A3 WO 2007108744 A3 WO2007108744 A3 WO 2007108744A3 SE 2007000254 W SE2007000254 W SE 2007000254W WO 2007108744 A3 WO2007108744 A3 WO 2007108744A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
modulators
preparation
salts
quinazolines
Prior art date
Application number
PCT/SE2007/000254
Other languages
French (fr)
Other versions
WO2007108744A2 (en
Inventor
Gunnar Nordvall
Ulrika Yngve
Original Assignee
Astrazeneca Ab
Gunnar Nordvall
Ulrika Yngve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Gunnar Nordvall, Ulrika Yngve filed Critical Astrazeneca Ab
Publication of WO2007108744A2 publication Critical patent/WO2007108744A2/en
Publication of WO2007108744A3 publication Critical patent/WO2007108744A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to new compounds of formula I, [Chemical formula should be inserted here. Please see paper copy] I or salts, solvates or solvated salts thereof, wherein Q, R1, R2, R3 and n are defined as in claim 1, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
PCT/SE2007/000254 2006-03-17 2007-03-15 Novel quinazolines as 5-ht6 modulators WO2007108744A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78324506P 2006-03-17 2006-03-17
US60/783,245 2006-03-17

Publications (2)

Publication Number Publication Date
WO2007108744A2 WO2007108744A2 (en) 2007-09-27
WO2007108744A3 true WO2007108744A3 (en) 2007-11-15

Family

ID=38522846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2007/000254 WO2007108744A2 (en) 2006-03-17 2007-03-15 Novel quinazolines as 5-ht6 modulators

Country Status (1)

Country Link
WO (1) WO2007108744A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2270002A1 (en) * 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
US9840482B2 (en) 2014-04-19 2017-12-12 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020445A1 (en) * 1997-10-02 2000-07-19 Eisai Co., Ltd. Fused pyridine derivatives
WO2001032646A2 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Sulfonamide derivatives
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
WO2005021530A1 (en) * 2003-08-29 2005-03-10 Glaxo Group Limited 8- (1-piperazinyl)- quinoline derivatives and their use in the treatment of cns disorders
WO2005058858A1 (en) * 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020445A1 (en) * 1997-10-02 2000-07-19 Eisai Co., Ltd. Fused pyridine derivatives
WO2001032646A2 (en) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Sulfonamide derivatives
WO2002100822A1 (en) * 2001-06-11 2002-12-19 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
WO2005021530A1 (en) * 2003-08-29 2005-03-10 Glaxo Group Limited 8- (1-piperazinyl)- quinoline derivatives and their use in the treatment of cns disorders
WO2005058858A1 (en) * 2003-12-19 2005-06-30 Biovitrum Ab Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder

Also Published As

Publication number Publication date
WO2007108744A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
TW200716529A (en) New compounds II
TW200801003A (en) Novel compounds
SE0104251D0 (en) Novel compounds
WO2004100865A3 (en) New benzimidazole derivatives
SG170069A1 (en) Quinoline derivatives
TW200626553A (en) Novel compounds
TW200639156A (en) New compounds
TW200833670A (en) Novel compounds 569
MY148634A (en) Pyridazinone derivatives
TW200736227A (en) New compounds III
MX2010009022A (en) 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use.
TW200730493A (en) Chemical compounds
TW200745122A (en) New compounds I
TW200728302A (en) Chemical compounds VI
MX2009003227A (en) Mglur5 modulators.
TW200740781A (en) Novel compounds
WO2007130821A3 (en) Mglur5 modulators ii
TW200512201A (en) New heterocyclic amides
SE0302546D0 (en) New compounds
TW200730512A (en) Novel compounds
TW200720262A (en) Novel compounds ii
TW200744612A (en) New combination
TW200745133A (en) New compounds II
SE0401763D0 (en) Compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07716067

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07716067

Country of ref document: EP

Kind code of ref document: A2